Disponible en: Costa M, Canale D, Filicori M, D'lddio S, Lenzi A
Sasson Moulavi, MD Board-certified in family medicine with 30+ years of experience in adult medicine
In December 2024, the FDA's Pharmacy Compounding Advisory Committee declined to include it on the 503A bulk drug substances list, meaning compounding pharmacies in the United States cannot legally produce it for individual prescriptions
This decline is closely linked to the loss of skin repair capacity and decreased dermal collagen density
Important safety information
Its use in assay development ensures the reliability and reproducibility of experimental results, supporting a wide range of research and quality control workflows involving peptide-based analytes